Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 719 matching trials from the live ClinicalTrials.gov search.
Conditions
Glioblastoma
Interventions
250 mg/m2 aldoxorubicin, 350 mg/m2 aldoxorubicin
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Duarte, California • Santa Monica, California • New Orleans, Louisiana + 1 more
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
Interventions
Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration
Other
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Solid Tumor
Interventions
SA53-OS (phase 1), SA53-OS (phase 2)
Drug
Lead sponsor
Lamassu Bio Inc
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Canton, Ohio • Cleveland, Ohio
Conditions
Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
Interventions
MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Drug
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Kansas City, Kansas • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Conditions
Soft Tissue Sarcoma
Interventions
Tigilanol Tiglate
Drug
Lead sponsor
QBiotics Group Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Globulin, Immune, Ganciclovir
Drug
Lead sponsor
American National Red Cross
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
Drug
Lead sponsor
Theravectys S.A.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
Conditions
Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Interventions
DSP107, Atezolizumab
Biological
Lead sponsor
Kahr Medical
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • Lake Mary, Florida + 4 more
Conditions
Metastatic Solid Tumors
Interventions
ERAS-4001, ERAS-4001 in combination
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Nashville, Tennessee • Houston, Texas • Irving, Texas + 2 more
Conditions
Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
Interventions
GSK4418959, PD-1 inhibitor
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more
Conditions
Head and Neck Neoplasm, Radiotherapy
Interventions
Prescription aerobic exercise
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

NCT00075049
Conditions
Malaria
Interventions
RTS,S with AS02A/AS01B adjuvant
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Silver Spring, Maryland
Conditions
Non-Hodgkin's Disease
Interventions
Nivolumab, Brentuximab Vedotin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
15 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
16
States / cities
Birmingham, Alabama • Miami, Florida • Tampa, Florida + 12 more
Conditions
Eating Disorder, Anorexia Nervosa, Bulimia Nervosa, Binge-Eating Disorder
Interventions
Peer mentorship, Social support mentorship, Recovery Record use with mentor
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
14 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatic Steatosis
Interventions
VLX103
Drug
Lead sponsor
Gyongyi Szabo
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more
Conditions
Crigler-Najjar Syndrome
Interventions
AT342
Genetic
Lead sponsor
Audentes Therapeutics
Industry
Eligibility
1 Year and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
The Bronx, New York • Strasburg, Pennsylvania
Conditions
Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
NBF-006
Drug
Lead sponsor
Nitto BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
9
States / cities
Beverly Hills, California • La Jolla, California • Tampa, Florida + 6 more
Conditions
Plaque Psoriasis
Interventions
DLX105-DMP
Drug
Lead sponsor
DelArrivo, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Alpharetta, Georgia • Philadelphia, Pennsylvania • San Antonio, Texas + 1 more
Conditions
Adenylosuccinate Synthase 1 Deficient Myopathy
Interventions
adenylosuccinic acid
Drug
Lead sponsor
Cure ADSSL1
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Alzheimer's Disease
Interventions
Bryostatin 1, Placebo
Drug
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Conditions
Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer, Lung Cancer, Melanoma, Ovarian, NSCLC
Interventions
SI-B036
Drug
Lead sponsor
SystImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
New Haven, Connecticut • Orlando, Florida • Sarasota, Florida + 4 more
Conditions
Lung Cancer, Breast Cancer
Interventions
BMS-986507, Osimertinib, Pembrolizumab, Nivolumab, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
14
States / cities
Birmingham, Alabama • Miami, Florida • Iowa City, Iowa + 9 more
Conditions
Lung Cancer
Interventions
High-Intensity Interval Training (HIIT), Moderate-Intensity Continuous Training (MICT)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts